Nutritional Adjuvants in Diabetes: Biotin and Chromium Picolinate as Emerging Therapeutic Agents

Insulin resistance and type 2 diabetes mellitus (T2DM) are serious worldwide health issues linked to dyslipidaemia, oxidative stress, impaired glucose metabolism, and persistent inflammation. Although their clinical significance is still unknown, micronutrients like chromium and biotin are thought to affect insulin signalling, glucose homeostasis, and lipid metabolism. The purpose of this review is to compile the preclinical, clinical, and epidemiological data that is currently available regarding the individual and combined effects of chromium and biotin on metabolic outcomes, insulin sensitivity, and glycaemic control.

Using databases like PubMed, Scopus, and Google Scholar, a thorough search of narrative literature was carried out. Included were pertinent experimental, clinical, and review studies evaluating the use of chromium and/or biotin supplements in diseases like metabolic syndrome, insulin resistance, and type 2 diabetes. With a focus on study design, dosage, duration, mechanistic pathways, and reported metabolic outcomes, the evidence was qualitatively examined.

Preclinical research repeatedly shows that biotin and chromium improve oxidative stress markers, lipid profiles, insulin sensitivity, and glucose tolerance. Increased GLUT-4 translocation, AMPK activation, insulin signalling pathway modulation (IRS-1/PI3K/Akt), and biotin-dependent enzyme regulation are some of the mechanisms that mediate these effects. Particularly in those with poor glycaemic control or micronutrient deficiencies, clinical trials show modest but significant improvements in fasting blood glucose, HbA1c levels, insulin resistance indices, and lipid parameters. Glycaemic control, dyslipidaemia, oxidative stress, and cardiovascular risk markers all seem to improve with combined supplementation. Additionally, epidemiological data point to a negative correlation between dietary chromium consumption and the risk of T2DM.

The results demonstrate the complementary functions of biotin and chromium in controlling the metabolism of fats and carbohydrates. When taken together, they may provide greater metabolic advantages than when taken separately. However, the generalisability of findings is constrained by variations in study design, participant characteristics, supplement formulations, and baseline nutritional status. The necessity of standardized research methods is highlighted by these discrepancies.

In general, chromium and biotin exhibit promise as supplemental treatments for the treatment of insulin resistance and type 2 diabetes, especially in populations with nutritional deficiencies or metabolic disorders. However, more extensive, carefully planned randomized controlled trials are needed to ascertain the best dosage, long-term safety, and clinical effectiveness.